Acetyl-CoA carboxylase

Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Retrieved on:

Thursday, May 26, 2022

Research, Infectious Diseases, FDA, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Acetyl-CoA carboxylase, Disease, Food, Epidemiology, U.S. Securities and Exchange Commission, Lipid metabolism, Review, Liver, Acci, Non-alcoholic fatty liver disease, YouTube, EMA, Twitter, WP, Prevalence, Kidney, Epidemic, Clinical trial, COVID-19, Inc., Fatty liver disease, Research, Facebook, Type 2, ACC, Fast Track, NYSE, Digestive, Inflammation, Hospital, NASH, Enzyme, Science, Vaccine, FDA, Gastroenterology, Fibrosis, Internal medicine, Ageing, LinkedIn, PFE, Senior, Risk, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Obesity, Liver disease, Safety, National Institute of Diabetes and Digestive and Kidney Diseases, Cirrhosis, NAFLD, Acetyl-CoA, Rusyns, News, Pharmaceutical industry, Dietary supplement, Pfizer, Nature Medicine, Diabetes

Receiving Fast Track designation from the FDA reinforces Pfizers belief in ervogastat/clesacostat as a potential treatment for NASH, a serious, progressive liver disease with no currently approved therapies, said James Rusnak, M.D., Ph.D., Senior Vice President and Chief Development Officer, Internal Medicine and Hospital, Pfizer.

Key Points:

Receiving Fast Track designation from the FDA reinforces Pfizers belief in ervogastat/clesacostat as a potential treatment for NASH, a serious, progressive liver disease with no currently approved therapies, said James Rusnak, M.D., Ph.D., Senior Vice President and Chief Development Officer, Internal Medicine and Hospital, Pfizer.
The results of this study, which also includes arms investigating ervogastat as monotherapy, will inform a potential Phase 3 development program.
Diacylglycerol O-acyltransferase 2 (DGAT2) and acetyl-CoA carboxylase (ACC) are two key enzymes that regulate lipid metabolism.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.

Yield10 Bioscience Field Test Results Show Seed Oil Content Increase in Camelina and Canola

Retrieved on:

Tuesday, March 1, 2022

WOBURN, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (Yield10 or the Company), an agricultural bioscience company, today announced that 2021 field test results show that the trait C3020 tested in Camelina and C3007 tested in canola produce increases in seed oil content.

Key Points:

WOBURN, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (Yield10 or the Company), an agricultural bioscience company, today announced that 2021 field test results show that the trait C3020 tested in Camelina and C3007 tested in canola produce increases in seed oil content.
Yield10 plans to include Camelina C3020 lines in its 2022 field testing program to collect additional oil content and seed yield data after obtaining permits from regulatory agencies.
Yield10 is developing a leading portfolio of novel traits designed to increase seed oil content in Camelina and major oilseed crops such as soybean and canola, said Kristi Snell, Ph.D., Chief Science Officer of Yield10 Bioscience.
The data generated in our 2021 field test program show that C3020 and C3007 boost oil content in Camelina and canola, respectively.

Nimbus Therapeutics and Schrödinger Extend Longstanding Collaboration to Discover Novel Therapeutics for Select Targets

Retrieved on:

Thursday, August 12, 2021

Biotechnology, Pharmaceutical, Health, Medical Supplies, Protein, MBA, Therapy, Drug discovery, Acetyl-CoA carboxylase, Acetyl-CoA, Machine learning, Industry, ACC, TYK2, Pathology, Pharmaceutical industry

Nimbus Therapeutics , a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the extension of its collaboration with Schrdinger, Inc. to discover and design small molecule therapeutics for a number of high-value targets using cutting-edge structure-based drug design approaches.

Key Points:

Nimbus Therapeutics , a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today announced the extension of its collaboration with Schrdinger, Inc. to discover and design small molecule therapeutics for a number of high-value targets using cutting-edge structure-based drug design approaches.
The agreement extends the collaboration between the two companies, which began in 2009, to advance the usage of computational methods in drug discovery.
Nimbus collaboration with Schrdinger over the past 12 years has been groundbreaking, deploying computational horsepower at an unprecedented scale in the industry, said Jeb Keiper, M.S., MBA, Chief Executive Officer of Nimbus.
Schrdingers deep computational capabilities, paired with Nimbus demonstrated expertise in structural biology, small molecule drug discovery and clinical development, provides fertile ground for designing breakthrough medicines over the next decade.

Global Acetyl-Coa Carboxylase Inhibitors Pipeline Insight Report 2021 Featuring Emerging Drugs Such as Firsocostat: Gilead Sciences & Clesacostat: Pfizer - ResearchAndMarkets.com

Retrieved on:

Thursday, May 13, 2021

Health, Pharmaceutical, Enzymes, Metabolism, Acetyl-CoA carboxylase, Acetyl-CoA, (acetyl-CoA carboxylase) kinase, Metabolic pathways, (acetyl-CoA carboxylase)-phosphatase

b'The "Acetyl-Coa Carboxylase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis Acetyl-CoA carboxylase inhibitors - Pipeline Insight, 2021 report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Acetyl-CoA carboxylase inhibitors pipeline landscape.\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products.

Key Points:

b'The "Acetyl-Coa Carboxylase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis Acetyl-CoA carboxylase inhibitors - Pipeline Insight, 2021 report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Acetyl-CoA carboxylase inhibitors pipeline landscape.\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products.
It further highlights the inactive pipeline products in this space.\nThis segment of the Acetyl-CoA carboxylase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery.
3+ key companies which are developing the Acetyl-CoA carboxylase inhibitors.
The companies which have their Acetyl-CoA carboxylase inhibitors drug candidates in the most advanced stage, i.e.

Poxel Presents New Preclinical Proof-of-Concept Results for PXL770 at the 3rd Annual Global NASH Congress

Retrieved on:

Wednesday, February 12, 2020

Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Other Health, Medical specialties, Branches of biology, Hepatitis, Medicine, RTT, Steatohepatitis, Non-alcoholic fatty liver disease, Adenosine monophosphate, Cholesterol, Fatty liver disease, Acetyl-CoA carboxylase

Poxel believes these benefits induced by PXL770 appear promising for the treatment of NASH.

Key Points:

Poxel believes these benefits induced by PXL770 appear promising for the treatment of NASH.
Non-alcoholic steatohepatitis (NASH) is a metabolic disease with no clear disease origin that is quickly becoming a worldwide epidemic.
Typical risk factors for NASH include obesity, elevated levels of blood lipids (such as cholesterol and triglycerides) and type 2 diabetes.
PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH.